|Mr. Umang Vohra B.E., M.B.A.||MD, Global CEO & Director||136.6M||N/A||46|
|Mrs. Samina Vaziralli||Exec. Vice Chairman||39M||N/A||41|
|Mr. Kedar Upadhye B.Com., AICWA, CS, MBA||Global Chief Financial Officer||31.3M||N/A||40|
|Mr. Raju Subrahmanyam||Global Head of Operations||N/A||N/A||N/A|
|Mr. Rajendra Chopra||Compliance Officer & Company Sec.||2.4M||N/A||N/A|
Cipla Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India. It offers active pharmaceutical ingredients; and formulations in various therapeutic areas, such as women's health, cardiovascular, children's health, dermatology and cosmeceuticals, diabetes, HIV-AIDS, hepatitis, oncology, infectious diseases and critical care, malaria, neurosciences, ophthalmology, osteoporosis, respiratory, and urology. The company also provides veterinary products, including anti-infectives, anti-inflammatories, anti-thyroids, immunosuppressants, parasiticides, nutraceuticals, and feed additives for various animals, including equine and companion care, livestock, poultry, swine, and aqua products. In addition, it offers inhalation therapy devices comprising metered-dose inhalers, dry powder inhalers, nasal sprays, nebulizers, and inhalation accessory devices, as well as spacers and related devices. The company also exports its products to Africa, the Middle East, Latin America, the Asia Pacific, North America, Australia, New Zealand, Russia, and internationally. Cipla Limited was founded in 1935 and is based in Mumbai, India.
Cipla Limited’s ISS Governance QualityScore as of February 1, 2018 is 2. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 1; Compensation: 7.